Latest Asx Companies News

InteliCare (ASX:ICR) is hitting a commercial inflection point, backed by a landmark $8.8 million contract with mecwacare and a growing pipeline across aged care sectors. Its AI-powered platform promises measurable improvements in care outcomes and operational efficiency.

Emyria Limited is progressing its national network of psychedelic-assisted therapy clinics, reporting durable patient outcomes, expanding funding sources, and benefiting from regulatory changes that broaden therapist eligibility.

Raiz Invest announces a leadership change with Brendan Malone stepping down as CEO and Craig Keary taking over, signalling a new chapter for the fintech amid steady growth.

Pointerra has locked in a multi-year deal with Origin Energy to deploy its Pointerra3D platform for automated monitoring of 750km of gas pipelines, marking a strategic expansion in its infrastructure analytics footprint.

Cash Converters reports solid 1H26 results driven by a growing loan book, expanding luxury retail footprint, and increased corporate store ownership across 15 countries.

Marvel Gold has completed an extensive drone magnetic survey at its Hanang Gold Project in Tanzania, revealing new mineralisation corridors and preparing to launch its first drilling campaign. Meanwhile, the company is exiting Mali due to regulatory hurdles, progressing the sale of its Yanfolila project.

InteliCare has inked a $200,000 contract to deploy its AI-powered monitoring platform across 65 retirement villas at Warrigal's new development, marking its first foray into the retirement living sector with potential for wider rollout.

BCAL Diagnostics has expanded its Avantect cancer blood tests nationally through major pathology networks, generating $88,000 in Q3 revenue from 91 tests. The company also submitted an initial Medicare reimbursement application for pancreatic cancer detection and is preparing to launch an enhanced BREASTESTplus 2.0 test in early 2027.

Compumedics maintains robust sales momentum but faces FY26 revenue timing challenges due to MEG installation delays and a cautious Somfit D rollout. The company expects solid year-on-year growth and positions for improved execution in FY27.

Orthocell’s Q1 FY26 revenue hits $3.2 million, buoyed by growing US sales of its Remplir nerve repair device and a robust $48 million cash position supporting global expansion.

Talius Group has inked a Master Services Agreement with Adventist Retirement Plus to roll out its Nurse Call and Sleep Systems across two Queensland villages, setting the stage for wider expansion and recurring revenue growth.

Lumos Diagnostics has secured its largest-ever order for FebriDx® following FDA clearance, signalling a major expansion in the US market opportunity.